{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:01:26Z","timestamp":1784851286206,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":59,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16237-2","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T06:14:14Z","timestamp":1779776054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of biliary drainage and biliary tract infection in unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: a multicenter, prospective cohort study (NAPOLEON-2)"],"prefix":"10.1186","volume":"26","author":[{"given":"Wataru","family":"Yoshioka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Oza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kitsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hozumi","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudai","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Jikuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norimasa","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sawase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Nio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"16237_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"16237_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics. 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"16237_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/MPA.0b013e318258055c","volume":"41","author":"S Egawa","year":"2012","unstructured":"Egawa S, Toma H, Ohigashi H, et al. Japan Pancreatic Cancer Registry;30th year anniversary:Japan Pancreas Society. Pancreas. 2012;41:985\u201392.","journal-title":"Pancreas"},{"key":"16237_CR4","first-page":"626","volume":"89","author":"MS De La Cruz","year":"2014","unstructured":"De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89:626\u201332.","journal-title":"Am Fam Physician"},{"key":"16237_CR5","first-page":"9345","volume":"20","author":"BR Boulay","year":"2014","unstructured":"Boulay BR, et al. Managing malignant biliary obstruction in pancreas cancer:choosing the appropriate strategy. World J Gastroenterol. 2014;20:9345\u201353.","journal-title":"World J Gastroenterol"},{"key":"16237_CR6","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"16237_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"16237_CR8","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","volume":"402","author":"ZA Wainberg","year":"2023","unstructured":"Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nabpaclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3):a randomised, open-label, phase 3 trial. Lancet. 2023;402:1272\u201381.","journal-title":"Lancet"},{"key":"16237_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (Napoli-1):A global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"16237_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/MPA.0000000000001455","volume":"49","author":"T Macarulla Mercad\u00e9","year":"2020","unstructured":"Macarulla Mercad\u00e9 T, Chen L-T, Li C-P, et al. Liposomal irinotecan + 5-FU\/LV in metastatic pancreatic cancer:subgroup analyses of patient, tumor, and previous treatment characteristics in the pivotal NAPOLI-1 trial. Pancreas. 2020;49:62\u201375.","journal-title":"Pancreas"},{"key":"16237_CR11","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/j.dld.2023.04.015","volume":"55","author":"G Gasparini","year":"2023","unstructured":"Gasparini G, Aleotti F, Palucci M, et al. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Dig Liver Dis. 2023;55:1750\u20136. 10.1016\/j. dld.2023.04.015.","journal-title":"Dig Liver Dis"},{"key":"16237_CR12","first-page":"377","volume":"12","author":"JL Buxbaum","year":"2011","unstructured":"Buxbaum JL, Biggins SW, Bagatelos KC, et al. Inoperable pancreatic cancer patients who have prolonged survival exhibit an increased risk of cholangitis. JOP. 2011;12:377\u201383.","journal-title":"JOP"},{"key":"16237_CR13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1186\/s12885-025-14992-2","volume":"25","author":"K Nishikawa","year":"2025","unstructured":"Nishikawa K, Otsuka T, Shimokawa M, Inagaki T, Komori A, Todaka A, et al. Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 study. BMC Cancer. 2025;25:1614. https:\/\/doi.org\/10.1186\/s12885-025-14992-2.","journal-title":"BMC Cancer"},{"key":"16237_CR14","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.1038\/s41598-024-63172-y","volume":"14","author":"T Kodama","year":"2024","unstructured":"Kodama T, Imajima T, Shimokawa M, et al. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer. Sci Rep. 2024;14:12422. https:\/\/doi.org\/10.1038\/s41598-024-63172-y.","journal-title":"Sci Rep"},{"issue":"C","key":"16237_CR15","doi-asserted-by":"publisher","first-page":"100150","DOI":"10.1016\/j.esmogo.2025.100150","volume":"8","author":"T Shirakawa","year":"2025","unstructured":"Shirakawa T, Shimokawa M, Otsuka T, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable or recurrent pancreatic cancer:a multicenter observational study (NAPOLEON-2). ESMO Gastrointest Oncol. 2025;8(C):100150. 10.1016\/j. esmogo.2025.100150.","journal-title":"ESMO Gastrointest Oncol"},{"key":"16237_CR16","doi-asserted-by":"crossref","unstructured":"Morris TP, White IR, Royston P. Tuning multiple imputation by predictive mean matching and local residual draws. BMC Med Res Methodol. 2014;14:75. https:\/\/doi.org\/10.1186\/1471-2288-14\u201375.","DOI":"10.1186\/1471-2288-14-75"},{"key":"16237_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"16237_CR18","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Bethesda, MD:U.S.: Department of Health and Human Services, National Institutes of Health; 2017."},{"key":"16237_CR19","doi-asserted-by":"publisher","first-page":"e200","DOI":"10.1016\/S1470-204530145-7","volume":"20","author":"SD Krens","year":"2019","unstructured":"Krens SD, Lassche G, Jansman FGA, et al. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. Lancet Oncol. 2019;20:e200\u20137. https:\/\/doi.org\/10.1016\/S1470-204530145-7.","journal-title":"Lancet Oncol"},{"key":"16237_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/dmr.2020.04.04","volume":"3","author":"S Noventa","year":"2020","unstructured":"Noventa S, Cherri S, Zaniboni A. Chemotherapy in advanced pancreatic cancer with hyperbilirubinemia. Dig Med Res. 2020;3:18. https:\/\/doi.org\/10.21037\/dmr.2020.04.04.","journal-title":"Dig Med Res"},{"key":"16237_CR21","doi-asserted-by":"publisher","first-page":"S213","DOI":"10.1016\/j.annonc.2020.04.461","volume":"31","author":"T Honda","year":"2020","unstructured":"Honda T, Takayuki O, Shimokawa M, et al. PD-5 Impact of biliary drainagefor unresectable pancreatic cancer treated with folfirinox or gemcitabine plus nab-paclitaxel:Results from the Napoleon study. Ann Oncol. 2020;31:S213.","journal-title":"Ann Oncol"},{"key":"16237_CR22","doi-asserted-by":"crossref","unstructured":"Yoshikawa-Kimura A, Taira K, Maruyama H et al. Influence of a biliary stent in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Med (Baltim). 2022;101:49.","DOI":"10.1097\/MD.0000000000032150"},{"issue":"8","key":"16237_CR23","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.3390\/cancers12082036","volume":"12","author":"M Lee","year":"2020","unstructured":"Lee M, Lee JC, Park JY, et al. The role of location of tumor in the prognosis of the pancreatic cancer. Cancers (Basel). 2020;12(8):2036.","journal-title":"Cancers (Basel)"},{"key":"16237_CR24","doi-asserted-by":"publisher","first-page":"e0155479","DOI":"10.1371\/journal.pone.0155479","volume":"11","author":"C L\u00fcbbert","year":"2016","unstructured":"L\u00fcbbert C, Wendt K, Feisthammel J, et al. Epidemiology and Resistance Patterns of Bacterial and Fungal Colonization of Biliary Plastic Stents:A Prospective Cohort Study. PLoS ONE. 2016;11:e0155479. https:\/\/doi.org\/10.1371\/journal.pone.0155479.","journal-title":"PLoS ONE"},{"key":"16237_CR25","doi-asserted-by":"crossref","unstructured":"Grafia I, Chumbita M, Segu\u00ed E et al. Epidemiology and risk factors for recurrence in biliary source bloodstream infection episodes in oncological patients. Microbiol Spectr. 2023;11. https:\/\/doi.org\/10.1128\/spectrum.02142\u201323.","DOI":"10.1128\/spectrum.02142-23"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16237-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16237-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16237-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:22:10Z","timestamp":1784848930000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16237-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16237"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16237-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8972664\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The NAPOLEON-2 study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of each participating institution. Written informed consent was obtained from all participants. The study was centrally approved by the institutional review board of Sasebo Kyosai Hospital (study ID 2021-09) and also approved by the institutional review board or ethics committee of each participating institution [Asakura Medical Association Hospital (148), Saiseikai Sendai Hospital (93), Saga Medical Center Koseikan (21-05-10-04), Miyazaki Prefectural Miyazaki Hospital (21\u2009\u2212\u200910), Saiseikai Kumamoto Hospital (987), Japanese Red Cross Nagasaki Genbaku Hospital (R3-676), Imamura General Hospital (NCR21-34), Kurume University Hospital (21063), Kagoshima Kouseiren Hospital (225), Kagoshima University Hospital (210081), NHO Kumamoto Medical Center (1101), Kagoshima City Hospital (2021-15), National Hospital Organization Saga Hospital (3\u20137), Fukuoka University Hospital (U21-742), Hamanomachi Hospital (2021-28), Oita University Hospital (2131), Japan Community Healthcare Organization Kyushu Hospital (776), Karatsu Red Cross Hospital (6-2-1), Izumi General Medical Center (65), Japanese Red Cross Kumamoto Hospital (457) and Kimitsu Chuo Hospital (625)] before the study and was conducted according to the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"891"}}